We’re pleased to welcome Dr. Nancy Messier and Dr. Thierry Abribat to our Board of Directors. Their complementary expertise in drug discovery, clinical development, and strategic leadership will strengthen our ability to advance FTX-101 and fulfill our mission of therapeutic innovation.
